These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Lipid management and cholesterol goal attainment in Norway. Ose L; Skjeldestad FE; Bakken IJ; Levorsen A; Alemao EA; Yin DD; Borgström F; Jönsson L Am J Cardiovasc Drugs; 2006; 6(2):121-8. PubMed ID: 16555865 [TBL] [Abstract][Full Text] [Related]
43. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Daskalopoulou SS; Mikhailidis DP Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035 [TBL] [Abstract][Full Text] [Related]
44. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946 [TBL] [Abstract][Full Text] [Related]
45. Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice. Gandhi SK; Järbrink K; Fox KM; Brandrup-Wognsen G Curr Med Res Opin; 2009 Dec; 25(12):2817-28. PubMed ID: 19916726 [TBL] [Abstract][Full Text] [Related]
46. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008 [TBL] [Abstract][Full Text] [Related]
47. Rosuvastatin--a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients. Schuster H Cardiology; 2003; 99(3):126-39. PubMed ID: 12824720 [TBL] [Abstract][Full Text] [Related]
49. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Rader DJ; Davidson MH; Caplan RJ; Pears JS Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340 [TBL] [Abstract][Full Text] [Related]
50. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Frolkis JP; Pearce GL; Nambi V; Minor S; Sprecher DL Am J Med; 2002 Dec; 113(8):625-9. PubMed ID: 12505111 [TBL] [Abstract][Full Text] [Related]
51. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
52. Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. Schectman G; Hiatt J Ann Intern Med; 1996 Dec; 125(12):990-1000. PubMed ID: 8967711 [TBL] [Abstract][Full Text] [Related]
53. Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting. Harley CR; Gandhi SK; Anoka N; Bullano MF; McKenney JM Am J Manag Care; 2007 Dec; 13 Suppl 10():S276-81. PubMed ID: 18095778 [TBL] [Abstract][Full Text] [Related]
54. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia. Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760 [TBL] [Abstract][Full Text] [Related]
55. Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration. Plakogiannis R; Cohen H Ann Pharmacother; 2007 Jan; 41(1):106-10. PubMed ID: 17200427 [TBL] [Abstract][Full Text] [Related]
56. Achieving lipid goals in real life: the Dutch DISCOVERY study. Bots AF; Kastelein JJ; Int J Clin Pract; 2005 Dec; 59(12):1387-94. PubMed ID: 16351669 [TBL] [Abstract][Full Text] [Related]
57. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425 [TBL] [Abstract][Full Text] [Related]
58. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. Krempf M; Simpson RJ; Ramey DR; Brudi P; Giezek H; Tomassini JE; Lee R; Farnier M Lipids Health Dis; 2015 May; 14():45. PubMed ID: 25985907 [TBL] [Abstract][Full Text] [Related]
59. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. Gentile S; Turco S; Guarino G; Sasso CF; Amodio M; Magliano P; Salvatore T; Corigliano G; Agrusta M; De Simone G; Gaeta I; Oliviero B; Torella R Diabetes Obes Metab; 2000 Dec; 2(6):355-62. PubMed ID: 11225965 [TBL] [Abstract][Full Text] [Related]
60. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]